Relative expression levels were calculated using the 2Ctmethod with 18S RNA as an internal control [40]

Relative expression levels were calculated using the 2Ctmethod with 18S RNA as an internal control [40]. == Statistics == Data are expressed as mean SEM. mineral density (BMD) and estimated bone strength, and deterioration of bone structure at the distal femoral metaphysis. Treatment with Scl-Ab largely restored BMD, bone structure, and bone mechanical strength. Histomorphometric analysis showed that Scl-Ab increased bone formation in animals with chronic SCI. In ex vivo cultures of bone marrow cells, Scl-Ab inhibited osteoclastogenesis, and promoted osteoblastogenesis accompanied by increased Tcf7, ENC1, and the OPG/RANKL ratio expression, and decreased SOST expression. Our findings demonstrate for the first time that Scl-Ab reverses the sublesional bone loss when therapy is usually begun after relatively prolonged spinal cord transection. The study suggests that, in addition to being a treatment option to prevent bone loss after acute SCI, sclerostin antagonism may be a valid clinical approach to reverse the severe bone loss that invariably occurs in patients with chronic SCI. Keywords:Spinal cord injury, Sclerostin, Bone formation, Bone mineral density, Trabecular bone volume == Introduction == The decline in bone mass and deterioration of the skeletal architecture are well-known consequence of spinal cord injury (SCI). More than 50% of individuals with chronic SCI will sustain a low-impact or osteoporotic fracture at some point subsequent to being paralyzed [1]. At the sublesional long-bone epiphyses, bone loss rate may approach ~ 1% per week for the first year following injury [2]. The greatest decreases in bone mass and the most common sites for fragility fractures are observed at the distal femur and proximal tibia [2]. Fractures lead to serious medical complications including pressure ulcer Haloperidol (Haldol) formation, increased pain, spasticity, and lower limb amputation [3]. Despite these serious clinical complications, currently there is no standard or well-accepted guideline for the diagnosis, prevention, or treatment of SCI-induced osteoporosis. Elucidation of the Wnt/-catenin signaling pathway in bone homeostasis has transformed our understanding of the cellular and molecular mechanisms in Haloperidol (Haldol) bone formation and resorption [47]. Recent studies suggest that sclerostin is usually a key regulator of SCI-induced bone loss [812]. Encoded by the SOST gene, sclerostin is usually a glycoprotein secreted primarily by osteocytes under physiological conditions, and is a potent inhibitor of bone formation [13,14]. Sclerostin binds to low-density lipoprotein receptor-related protein 5/6 and antagonizes the Wnt signaling pathway [15,16]. Downregulation of sclerostin is usually associated with increased osteogenesis and bone mass [17,18]. Mechanical stimulationin vivodramatically reduces the expression of sclerostin by osteocytes [19]. Moreover, targeted deletion of sclerostin in mice increased bone formation, bone mass and strength [17,20], and these animals are resistant to unloading-induced bone loss [20]. In humans, mechanical unloading of bone occurs in various conditions that result in paralysis and the inability to ambulate. Therefore, the association between sclerostin and bone loss may be anticipated to be strongest in pathological conditions that result in individuals who occupy the lowest end of the activity spectrum, such as those with chronic SCI. Recent studies conducted by our group and other Haloperidol (Haldol) investigators have shown that pharmacological inhibition of sclerostin with a Haloperidol (Haldol) sclerostin Haloperidol (Haldol) antibody (Scl-Ab), when administered immediately after lesion, prevents bone loss in animals with either acute motor-incomplete [11] or motor-complete SCI [10]. We have also reported that sclerostin-deficient mice are resistant to the major sublesional bone loss that invariably follows SCI [12]. However, other highly clinically relevant questions should be resolved, such as whether sclerostin inhibition is able to reverse bone loss in individuals with SCI who have been injured for several years and have had substantial sublesional bone loss, which represents the vast majority of the SCI populace. Patients with SCI who are chronically immobilized are appreciated to develop several pathological changes that may contribute to the extensive loss of sublesional bone mass that occurs after SCI, including those of systemic hormonal, metabolic, and inflammatory disorders [10]. We hypothesize that Scl-Ab is able to reverse bone loss that has occurred after chronic motor-complete SCI. To test this hypothesis, an established rat model of sublesional bone loss following complete SLCO5A1 spinal cord transection [10,21,22] was used to investigate the effects around the sublesional skeleton after 8 weeks of treatment with Scl-Ab that was initiated 12 weeks after motor-complete SCI. Jin et al. reported that 4 weeks after SCI in rodents, the neural regenerative response has subsided, an astrocytic scar has been established at the injury site,.